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(reviewed in Garneau et al., 2007; Meyer et al., 2004; and Parker
and Song, 2004). In the 50/30 mRNA decay pathway, the mRNA
50 cap structure is removed by decapping enzymes when
a substantial part of the poly(A) tail has been degraded. After
this decapping event, the 50/30 Xrn1 exonuclease will degrade
the remaining part of mRNA starting at the 50 end of themRNA. In
the 30/50 mRNA decay pathway, the cytoplasmic exosome
complex will continue to degrade the mRNA body in the 30/50
direction after the mRNA poly(A) tail has been removed by the
deadenylation event.
In mammalian cells, poly(A)-specific ribonuclease (PARN) is
one of the known deadenylases responsible for mRNA deadeny-
lation (A˚stro¨m et al., 1991; Ko¨rner andWahle, 1997; Ko¨rner et al.,
1998; Martinez et al., 2000). Biochemical studies have shown
that PARN is an mRNA cap-interacting protein (Dehlin et al.,
2000; Gao et al., 2000; Martinez et al., 2001). The binding of
the mRNA 50 cap stimulates the catalytic activity of PARN puri-
fied from mammalian cells (Dehlin et al., 2000; Gao et al.,
2000; Martinez et al., 2000) and enhances the processivity of
PARN action (Martinez et al., 2001). PARN belongs to the RNase
D superfamily of nucleases and harbors high specificity toward
single-stranded poly(A) (Martinez et al., 2000). It is a metal ion-
dependent, highly processive, and multidomain exonuclease
composed of the nuclease domain, the R3H domain, and the
RNA recognition motif (RRM) (Figure 1A). The nuclease domain
contains the catalytic site and is responsible for the cleavage
of the poly(A) tail, whereas the R3H domain has been implicated
in poly(A) binding, although its exact role is still not clear (Marti-
nez et al., 2001; Nilsson et al., 2007; Ren et al., 2002; Wu et al.,
2005). Our previous structural work on the N-terminal domain
of human PARN (hPARN), containing the nuclease and R3H
domains, demonstrated that a homodimeric form of PARN is
the structural and functional unit (Wu et al., 2005).
Biochemical and mutational studies of the hPARN RRM
showed that the RRMby itself binds the cap and also contributes
to poly(A)-specificity and that the cap- and poly(A)-binding sites
on the RRMare both functionally and structurally separated from
each other (Nilsson et al., 2007). One tryptophan (W475 in
human) within the RRM has been identified as an essential
residue required for cap binding. Consistent with this finding,SUMMARY
Poly(A)-specific ribonuclease (PARN) is a homodi-
meric, processive, and cap-interacting 30 exoribonu-
clease that efficiently degrades eukaryotic mRNA
poly(A) tails. The crystal structure of a C-terminally
truncated PARN in complex with m7GpppG reveals
that, in one subunit, m7GpppG binds to a cavity
formed by the RRM domain and the nuclease
domain, whereas in the other subunit, it binds almost
exclusively to the RRM domain. Importantly, our
structural and competition data show that the cap-
binding site overlaps with the active site in the
nuclease domain. Mutational analysis demonstrates
that residues involved in m7G recognition are crucial
for cap-stimulated deadenylation activity, and those
involved in both cap and poly(A) binding are impor-
tant for catalysis. A modeled PARN, which shows
that the RRM domain from one subunit and the
R3H domain from the other subunit enclose the
active site, provides a structural foundation for
further studies to elucidate the mechanism of
PARN-mediated deadenylation.
INTRODUCTION
The cap structure and the poly(A) tail are characteristic features
of eukaryotic mRNA and are important for controlling RNA pro-
cessing, transport, translation, and stability (reviewed inGarneau
et al., 2007;Meyer et al., 2004; Parker and Song, 2004; and Shat-
kin and Manley, 2000). Many cap-binding proteins, such as the
nuclear (CBP20) or the cytoplasmic (eIF4E) cap-binding proteins
(Izaurralde et al., 1994; Sonenberg et al., 1978; von der Haar
et al., 2004), and poly(A)-binding proteins, such as the nuclear
or cytoplasmic poly(A)-binding proteins (PABP), are involved in
these processes (reviewed in Kuhn and Wahle, 2004). Further-
more, both structures and, especially, the poly(A) tail are crucial
for proper regulation of mRNA decay. Two general mRNA decay
pathways have been identified, both of which are initiated byl rights reserved
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D EStructure 17, 276the NMR and crystal structures of the RRM domain of PARN in
complex with the cap analog revealed that the m7G base of
the cap analog stacks with the aromatic side chain of W468 in
mice, corresponding to W475 in humans (Monecke et al.,
2008; Nagata et al., 2008). However, the molecular mechanism
underlying the cap-stimulated deadenylation activity and how
cap recognition and poly(A) cleavage are coordinated to each
other remain elusive.
To understand the molecular basis of cap recognition by
PARN and how this process increases its enzymatic processiv-
ity, we have determined the crystal structure of a mouse PARN
(mPARN) polypeptide containing the nuclease, R3H, and RRM
domains in complex with the cap analog, m7GpppG, at a resolu-
tion of 3.0 A˚. The structure reveals a novel cap-bindingmode that
is distinct from other cap-binding proteins. Structural and muta-
tional analyses showed that the RRM confers the cap recogni-
tion specificity with the nuclease domain, providing additional
binding affinity. We conclude that the cap-binding and active
sites partially overlap both structurally and functionally in the
nuclease domain.
RESULTS
Structure Determination
A C-terminally truncated mPARN (residues 1–510, designated
mPARNt) containing the nuclease, the R3H, and the RRM
domains was cloned and expressed as a His-tag fusion protein.
To facilitate protein crystallization, the flexible His-tag region at
the N terminus was removed by PreScission protease. The sele-
nomethione (SeMet)-substituted mPARNt was cocrystallized
with the m7GpppG cap analog. The structure of mPARNt in
complex with m7GpppG was determined at a resolution of
3.0 A˚ by a combination of SeMet SAD and themolecular replace-
ment using the coordinates of apo-hPARNn (PDB code: 2A1R)
and the NMR structure of mouse RRM domain (1WHV). There
are two mPARNt molecules in the asymmetric unit with each
molecule binding to one cap analog. The final model was refined
to working and R free factor of 29.8% and 33.3%, respectively
(see Experimental Procedures and Table 1). Five regions
(residues 37–44, 149–249, 365–367, 393–401, and 504–510) in
molecule A and four regions in molecule B (residues 145–250,
358–369, 392–404, and 506–510) are disordered.
Overall Structure
mPARNt forms a homodimer in the structure of the mPARNt-
m7GpppG complex via the nuclease domain, with each subunit
Figure 1. The Structure of the mPARNt-m7GpppG Complex
(A) Domain organization of mPARN showing the nuclease domain (green), the
R3H domain (red), and the RRM domain (cyan).
(B) A ribbon diagram of the mPARNt-m7GpppG complex. The nuclease
domains in the closed and open forms are colored in green and yellow, respec-
tively. The RRM domains in the closed and open forms are colored in cyan and
purple, respectively. The m7GpppG molecules are shown in stick model.
(C) Superimposition of the closed and open forms of mPARNt. The nuclease
domains are colored as in panel B. The RRM domains in the closed and
open forms are colored in cyan and purple, respectively.
(D and E) 3.0A˚ simulated annealing (SA) omit maps contoured at 2s covering
m7GpppG in the closed and open forms, respectively.–286, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 277
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278 Structure 17, 276–286, February 13, 2009 ª2009 Elsevier Ltd Atwo subunits (Figure 1C). This difference in the orientations of
the RRM domains with respect to the nuclease domains leads
to markedly different cap-binding modes in both subunits. In
one subunit (referred to as closed form), m7GpppG is located
in the cavity formed by the RRM and the nuclease domain, and
has well-defined electron density, whereas in the other subunit
(referred to as open form), only one guanosine residue (m7G) of
m7GpppG that interacts with the RRM domain is well ordered
(Figures 1D and 1E).
The Cap-Binding Site Is Formed by Both the RRM
and Nuclease Domains
The 7-methyl guanosine group and the following guanosine
group cannot be unambiguously differentiated in the electron
densitymap of themPARNt-m7GpppG complex. However, there
is a strong electron density facing to W468 in the mPARNt-
m7GpppG complex (Figures 1D and 1E). Moreover, a previous
study showed that the RRM of hPARN by itself specifically inter-
acted with the two cap analogs, m7GTP andm7GpppG, and that
the W475 residue of hPARN (corresponding to W468 of mPARN;
see Figure S1 available online) was critical for RRM-mediated
cap analog binding (Nilsson et al., 2007). Thus, we fitted a model
of m7GpppG into the electron density in each subunit, withW468
stacking against the m7G group. The correctness of this fitting is
confirmed by the most recently determined structures of the
RRM domain of PARN in complex, with the cap analog showing
that the m7G base stacks withW468 in mouse or W475 in human
(Monecke et al., 2008; Nagata et al., 2008).
In the mPARNt-m7GpppG complex, both the RRM and
nuclease domains contribute to cap binding, with the nuclease
domain involved in more-extensive interactions with the cap in
the closed form than in the open form (Figure 2). In both forms,
the m7G recognition is conferred by residues from b2 and the
a1-b1 loop of the RRM domain (Figure 2 and Figure S1). Specif-
ically, the indole group of W468 in the RRM stacks against the
m7G base with a distance of 3.4A˚ in a coplanar orientation.
Additionally, the carbonyl groups of W449 and D471 in the
closed form make contacts with the N1 and N2 of the m7G,
respectively.
Our previousmutational study of the hPARNRRMshowed that
alanine substitutions ofW475 andW456 in the RRMaffected cap
binding to different extent (Nilsson et al., 2007). It is likely that the
severe effect of the W475A mutation was due to an interruption
of the stacking interaction between this tryptophan residue and
the 7-methyl guanine moiety of the cap. Mutation of W456 (cor-
responding to W449 in mice; Figure S1) to an alanine perturbed
slightly the cap-binding property of hPARN. In the mPARNt-
m7GpppG complex, W449, F445, L454, Y497, and L457 form
a hydrophobic core that stabilizes the RRM core structure
(data not shown). A mutation of W449 would most likely distort
the main-chain conformation of the a1-b1 loop, leading to the
reduced cap-binding ability. The complex structure enables us
to attribute the functional character to W475 (W468 in mice)
and the structural role of W456 (W449 in mice) upon cap binding.
Previous studies showed that full-length hPARN binds
m7GpppG 2-fold better than m7GTP (Nilsson et al., 2007).
The binding affinity of the hPARN RRM domain to m7GpppG or
m7GTP was about 7-fold lower than its binding affinity to the
full-length protein, implying that other parts or domains ofbinding to one cap analog (Figure 1B). The dimerized nuclease
domain is structurally identical to that in our previous hPARN
nuclease domain structure (PDB code: 2A1R) (Wu et al., 2005).
Although the electron density map clearly showed some features
of the R3H domain in the apo-hPARN structure (Wu et al., 2005),
the quality of the electron density is not good enough to allow us
to build any residues in the R3H domain with confidence. Given
this fact, the R3H domains in both subunits in the mPARNt-
m7GpppG complex are assumed to be disordered.
The RRM domain is composed of a four-stranded antiparallel
b sheet and two a helices packed against the b sheet and is con-
nected to the nuclease domain by a hinge region consisting of
residues 429–439 (Figure 1B). Surprisingly, the two subunits of
mPARNt in themPARNt-m7GpppG complex adopt very different
conformations. Superposition of the nuclease domains showed
that the orientation of the RRM domains differ by 30 in the
Table 1. Data Collection and Refinement Statistics
Data collection
Space group P212121
Unit cell dimension
a/b/c (A˚) 58.01/128.35/176.84
a/b/g () 90.00/90.00/90.00
Resolution range (A˚) 503.0
Completeness (%) 96 (96)
Unique reflections (N) 29,592
Redundancy 6.9 (5.5)
Rmerge (%)
a 10.1 (32.7)
I/s 4.5 (2.3)
Refinement
Resolution (A˚) 203.0
Used reflections (N) 24,512
Total atoms (N) 6310
Protein atoms 6126
Nucleotide atoms 104
Water molecules 80
Rwork (%)
b 29.8
Rfree (%)
c 33.3
r.m.s deviation from ideal values
Bond distance (A˚) 0.013
Bond angle () 1.533
Ramchandran plot
Most favored region 85.5%
Allowed region 14.2%
Generously allowed region 0.3%
Disallowed region 0%
Values in parentheses indicate the specific values in the highest resolu-
tion shell (3.23.0 A˚).
a Rmerge =
PjIj- < I > j/
P
Ij, where Ij is the intensity of an individual reflec-
tion, and < I > is the average intensity of that reflection.
b Rwork =
PjjFoj - jFcjj/
PjFcj, where Fo denotes the observed structure
factor amplitude, and Fc denotes the structure factor amplitude calcu-
lated from the model.
c Rfree is as for Rwork but calculated with 5.0% of randomly chosen reflec-
tions omitted from the refinement.ll rights reserved
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Figure 2. The m7GpppG-Binding Site
(A) Stereo diagram of the mPARNt-m7GpppG interface in the closed form.
(B) The mPARNt-m7GpppG interface in the open form. Residues involved in the interaction and m7GpppG are shown in stick models. The color coding for
mPARNt is as in Figure 1B.Structure 17, 276the syn conformation. Most of the noncovalent contacts stabi-
lizing the phosphate bridge and the second nucleoside are
lost. Only the D471 carboxylate and T41 make direct contacts
with the first ribose and the first phosphate group of the cap,
respectively, whereas T44 contacts the first phosphate group
via a water molecule.
It should be noted that residues involved in the cap recognition
(i.e., D28, I34, R53, L57, H280, N281, L283, L284, K319, N333,
S335, L336, M418, R419, W449, W468, D470, and D471) are
highly conserved in PARN family proteins, thereby underscoring
their functional importance (Figure 2 and Figure S1). Taken
together, these observations suggest that the nuclease domain
provides additional binding affinity for cap recognition, particu-
larly in the closed form.
The Cap-Binding Site of PARN Overlaps with the Active
Site in the Nuclease Domain
The observations that some residues (i.e., D28 and I34) that have
previously been shown to be critical for catalysis of hPARN are
involved in cap binding (Figure 2A) imply that the cap-binding
and active sites of PARN must overlap to some extent.PARN contributed to m7GpppG or m7GTP binding, although the
RRM contributed primarily. In agreement with these biochemical
results, our structure showed that the nuclease domain is also
involved in cap binding (Figure 2).
In the closed form (Figure 2A), the 7-methylguanosine nucleo-
side assumes the anti conformation. Residues I34, L57, L283,
L284, andM418 and themethyl group of R53 form a hydrophobic
pocket for the first transcribed guanosine nucleotide. Of these
residues, L284 and M418 clamp the guanosine and thus
contribute significantly to the recognition of the first transcribed
nucleotide of mRNA. The OD1 group of D28 interacts indirectly
with the second ribose group via a water molecule. N281 makes
multiple van der Waals contacts with O5 and O4 of the second
ribose and N2 and N3 of the guanine base. In addition, the
hydroxyl group of S335 contacts the second phosphate group.
The NZ group of K319 contacts both the second and third phos-
phate groups. Furthermore, the third phosphate group makes
multiple contacts with K319, H280, one water molecule, and
the amino group of L336.
In the open form (Figure 2B), the 7-methylguaninemoiety is still
stackedwith theW468 indol ring, but them7G nucleoside adopts–286, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 279
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Crystal Structure of the PARN-Cap ComplexConsistent with this notion, superposition of the mPARNt-
m7GpppG complex in the closed form with the hPARNn-poly(A)
complex (Wu et al., 2005) showed that the bound m7GpppG in
the mPARNt-m7GpppG complex overlaps substantially with the
bound poly(A) in the hPARNn-poly(A) complex (Figure 3A). The
phosphate linkage and the G base of m7GpppG colocalize with
A B
poly(A)
 G
RRM RRM
poly(A)
 G
nuclease domain
nuclease domain
C
E F
m GpppG7m G7
A9A8
A10
m GpppG7
m G7
A10A8 A9
D
Figure 3. Poly(A) and m7GpppG Compete
with Each Other for Binding to PARN
(A and B) Superimposition of the bound A3 in the
hPARNn-poly(A) complex with the m7GpppG
molecule in the closed form (A) and in the open
form (B). Color coding for mPARNt is as in
Figure 1B. A3 and m
7GpppG are shown in stick
models with carbon atoms colored in yellow and
gray, respectively.
(C) ITC titration of m7GpppG into mPARNt.
(D) ITC titration of A10 into mPARNt.
(E) ITC titration of A10 into mPARNt in the presence
of 2.5-fold excess of m7GpppG.
(F) ITC titration of m7GpppG into mPARNt in the
presence of 2.5-fold excess of A10. The upper
panels show the experimental data, and the lower
panels show the integrated heats for each injection
together with the single-site model curves fitted to
them.
the A8 and A9 bases, respectively, in the
hPARNn-poly(A) complex, suggesting
that residues involved in the cap binding
may be important for catalytic activity of
PARN as well. While in the open form,
only the disordered G base overlaps to
a minor extent with the adenine base A8
(Figure 3B), which was also poorly
ordered in the structure of the hPARNn-
poly(A) complex (Wu et al., 2005). These
results suggest that, in the closed form,
binding of m7GpppG and poly(A) tail is
mutually exclusive in a single PARN
subunit, whereas the open form allows
both cap and poly(A) tail binding simulta-
neously.
To examine whether m7GpppG and
poly(A) compete with each other for
binding toPARN, isothermal titration calo-
rimetry assays were performed. Titration
of m7GpppG into mPARNt showed that
m7GpppG binds to mPARNt with KD of
2.1 mM at a molar ratio of 1.0 (Figure 3C
and Table 2), suggesting that two cap
analogs bind to one mPARNt dimer. This
finding is consistent with the two cap-
binding sites observed in the structure.
Ten-mer oligo(A) (A10) binds to mPARNt
with nanomolar affinity (KD = 0.06 mM;
Figure 3D and Table 2) at a molar ratio of
1.0, suggesting that two A10 molecules
bind to one PARNdimer. The tight binding
of A10 to PARN can probably be attributed
to the high-affinity binding of A10 to the canonical RNA-binding
site on the RRM domain (Nilsson et al., 2007) and the binding of
the 30 end of A10 to the catalytic site in the nuclease domain
(Wuet al., 2005). ITC competition assays showed that the binding
of A10 to mPARNt was reduced by 3-fold in the presence of
m7GpppG (apparent dissociation constant [KD
app] = 0.17 mM;280 Structure 17, 276–286, February 13, 2009 ª2009 Elsevier Ltd All rights reserved
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Structure 17, 276In addition to the previously identified cap-binding-defective
mutants, hPARN(W456A) and hPARN(W475A) (Nilsson et al.,
2007), we identified another mutant polypeptide, hPARN(N288A),
that was severely defective in binding both cap analogs and
seven mutant polypeptides—hPARN(D28A), hPARN(I34A),
hPARN(L291A), hPARN(K326A), hPARN(N340A), hPARN(S342A),
and hPARN(R426A)—that were affected in binding to at least one
of the cap analogs.
Next, we investigated the catalytic performance of the mutant
hPARN polypeptides using three different kinds of RNA
substrates—A3, A20, and noncapped L3(A30). The A3 substrate
primarily probes the hydrolytic activity and poly(A)-binding prop-
erty of the PARN active site, and the A20 substrate will rank the
mutant polypeptides, because this substrate examines both
hydrolytic activity in the active site and poly(A) binding within
and outside the active site, whereas the L3(A30) substrate will
provide information regarding the catalytic efficiency when
a substrate resembling noncapped mRNA substrates is used.
Furthermore, the catalytic efficiency of PARN activity can accu-
rately be quantified when the noncapped L3(A30) substrate is
used, because it is possible to follow and quantify the release
Table 3. Summary of hPARN-Cap Analog Equilibrium
Dissociation Constants
hPARN polypeptidea
KD ± DKD (mM)
b
m7GTP m7GpppG
PARNc 1.59 ± 0.11 0.90 ± 0.02
PARN(D28A) 2.71 ± 0.18 1.03 ± 0.05
PARN(I34A) 6.8 ± 0.7 3.05 ± 0.14
PARN(N288A) >1000 >1000
PARN(L291A) 9.8 ± 1.0 1.32 ± 0.15
PARN(K326A) 2.36 ± 0.16 1.83 ± 0.19
PARN(N340A) 2.34 ± 0.08 0.88 ± 0.06
PARN(S342A) 1.9 ± 0.4 2.4 ± 0.6
PARN(M425A) 1.7 ± 0.13 0.96 ± 0.04
PARN(R426A) 3.7 ± 0.4 3.1 ± 0.3
PARN(W456A)c 5.6 ± 1.4 6.4 ± 0.8
PARN(W475A)c >1000 >1000
Determined by intrinsic protein fluorescence quenching in 20 mM
HEPES-KOH (pH 7), 100 mM KCl, 1.5 mM MgCl2, 0.2 mM EDTA,
0.5 mM DTT, at 20C.
aPARN mutants were generated by site-directed mutagenesis.
b Listed values are weighed averages ± experimental errors resulting
from at least three independent titration series.
cData from Nilsson et al., 2007.Figure 3E and Table 2), whereas the binding of m7GpppG to
mPARNt was reduced by 12-fold (KD
app = 10.6 mM; Figure 3F
and Table 2) in the presence of A10. Both interactions of mPARNt
with the cap and A10 are enthalpy favorable, and the molar
enthalpy change for the cap binding is twice more negative
than that for A10. Strikingly, titration of mPARNt with A10 after
previous saturation of the protein by the cap analog leads to
a positive enthalpy change. The observed sign inversion of DH
suggests that most of the previously bound cap molecules are
expulsed from the same or closely neighboring binding site by
A10 as a result ofmuch higher affinity of the latter. Taken together,
these results strongly support the overlappedbinding sites of cap
and poly(A) observed in the structure and suggest that these
overlapped binding sites are functionally relevant.
Functional Analysis of the Cap-Binding Site
To further characterize the cap-binding site and to investigate
whether we could identify amino acids that play dual functional
roles in both cap-binding and hydrolytic activity of PARN, we
performed a site-directed mutational and functional analysis of
hPARN (Table S1). For this analysis, we specifically targeted
amino acid residues whose side chains were predicted from
the mPARNt-m7GpppG complex to play a role in cap structure
recognition and binding.
First we determined, by using fluorescence spectroscopy, the
equilibrium dissociation constants (KD) for the hPARN-m
7GTP
and hPARN-m7GpppG interactions (Table 3 and Figure S2).
The shape of the titration curves for hPARN corresponds to
a typical binding isotherm describing one type of binding site (Ef-
tink, 1997), in accordance with what was observed by the ITC
(Figure 3C). The hPARN-cap affinity is too weak to determine
the stoichiometry directly from the numerical analysis of the fluo-
rescencedata (Niedzwiecka et al., 2007), but the crystal structure
and the ITC results suggest that two cap molecules can bind to
the PARN dimer concurrently (Figures 1B and 3C). The question
is how the structural differences are reflectedby thebinding ener-
getics. As we can see from Table 3, the dissociation constant for
thedinucleotide capanalog is only less than2-fold lower than that
for themononucleotide. In terms of the free energy of binding, the
KD values correspond to DG
 of 8.11 and 7.77 kcal/mol,
respectively. The difference is not significant, although the first
transcribed nucleoside forms a network of noncovalent contacts
with the protein (Figure 2A). By analogy, the affinity of the cap-
binding site in the closed conformation, where both cap nucleo-
tides are bound, will be only slightly stronger than the affinity of
the open conformation. Hence, the two structurally different
cap-binding sites can show similar energetic behavior, being
indistinguishable in the titration assays.Table 2. Summary of Isothermal Titration Calorimetry Measurements
Protein in ITC cell Ligand in syringe KD, mM DH, kcal/mol T DS, kcal/mol n
mPARNt m7GpppG 2.1 ± 0.07 19.3 ± 0.17 11.7 1.08 ± 0.01
mPARNt A10 0.06 ± 0.005 8.6 ± 0.05 1.02 1.01 ± 0.004
mPARNt + 2.5x m7GpppG A10 0.17 ± 0.01
a 3.57 ± 0.03a 12.6a 0.99 ± 0.004
mPARNt + 2.5x A10 m
7GpppG 10.6 ± 1.2a 5.22 ± 0.22a 1.41a 1.0b
a The apparent values of the dissociation constants and the resultant thermodynamic parameters, determined in the competition assay using a single-
site model.
b Fixed value.–286, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 281
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Figure 4. Residues Involved in Cap Binding
Are Important for PARN-Mediated Deadeny-
lation
(A) 50 nM of hPARN or mutant hPARN polypep-
tide, as indicated, was incubated with 1 mM 50-end
32P-labeled A3 substrate. Reaction products, A2
and A1, were separated by TLC, and the resulting
fluorogram is shown. The hydrolytic activity of
each polypeptide was investigated during at least
three independent experiments. Representative
TLC patterns are shown.
(B) 10 nMof hPARN ormutant hPARN polypeptide,
as indicated, were incubated with 25 nM 50-end
32P-labeled A20 substrate. Reaction products
were separated by denaturing 25% polyacryl-
amide gel electrophoresis, and the resulting fluoro-
gram is shown. The positions of reaction products
are as indicated. The hydrolytic activity of each
polypeptide was investigated during at least three
independent experiments. Representative electro-
phoretic fractionation patterns are shown.
(C) 10 nM hPARN or mutant hPARN polypeptide,
as indicated, were incubated with 50 nM noncap-
ped L3(A30) substrate, radioactively labeled in its
poly(A) tail. Released AMP products were fraction-
ated by TLC. The amount of released AMP was
quantified, and the resulting reaction rates—nmol
AMP/(min*mg polypeptide)—based on at least
three independent experiments, were calculated.
Error bars represent 95% confidence intervals.
(D) hPARN or mutant hPARN polypeptide, as indi-
cated, was incubated with 10 nM of m7GpppG-
capped or noncapped L3(A30) substrate for 10
min in 30C under phosphate buffer conditions
(see Experimental Procedures). Released AMP
products were fractionated by TLC (Figure S3). The cap-stimulatory effect was measured by calculating the ratio of the released amount of AMP from a reaction
where hPARN or mutant hPARN polypeptide was incubated with a m7GpppG-capped L3(A30) substrate over the amount of released AMP from a reaction where
hPARN or mutant hPARN polypeptide was incubated with a noncapped L3(A30) substrate. Each bar represent mean values of ratios using 2, 4, 8, and 16 nM
hPARN or mutant hPARN polypeptide from at least three independent experiments. Error bars represent 95% confidence intervals.of the AMP product (A˚stro¨m et al., 1991). The results from this
analysis are summarized in Figures 4A–4C. Three classes of
mutant hPARN polypeptides were identified: (1) a hydrolytically
inactive or severely defective group including hPARN(D28A),
hPARN(I34A), and hPARN(K326A); (2) a hydrolytically active
group including hPARN(N288A), hPARN(L291A), hPARN(N340A),
hPARN(S342A), hPARN(M425A), and hPARN(R426A), which
revealed deficiencies when some of the substrates were used;
and (3) one hydrolytically nondefective mutant polypeptide,
hPARN(W475A). The catalytic performance of some of
these mutant polypeptides—hPARN(D28A), hPARN(I34A),
hPARN(K326A) and hPARN(W475A)—have been investigated
earlier, and the current study is in keeping with those studies
(Ren et al., 2004; Ren et al., 2002; Wu et al., 2005).
Earlier studies (Balatsos et al., 2006; Nilsson et al., 2007) have
revealed that the cap-stimulatory effect on PARN cannot be
recovered when recombinant hPARN purified from bacteria is
used. However, we have recently established a phosphate-buff-
ered in vitro deadenylation system wherein a 2.5-fold cap-stim-
ulatory effect can be recovered when bacterially expressed
hPARN is used (see Experimental Procedures, Figure 4D, and
Figure S3). The magnitude of this stimulatory effect resembles
the 3-fold effect that was observed when we used native
PARN purified from calf thymus (Martinez et al., 2001). Having282 Structure 17, 276–286, February 13, 2009 ª2009 Elsevier Ltd Allestablished this new in vitro system, we investigated whether
any of the two cap-binding-deficient and hydrolytically active
mutants—hPARN(N288A) and hPARN(W475A)—were affected
in cap stimulation (Figure S3). The results are summarized in
Figure 4D and show that hPARN(W475A) did not reveal any
cap-stimulatory effect, whereas the hPARN(N288A) mutant
was slightly affected.
In conclusion, nine of the tested mutant polypeptides revealed
either major or minor deficiencies in their deadenylation proper-
ties, suggesting that the targetedamino acid residuesare required
for proper performance of PARN deadenylation activity. Signifi-
cantly, at least two of the mutant polypeptides—hPARN(I34A)
and hPARN(N288A)—were clearly defective in both cap binding
and deadenylation activities. Furthermore, mutations of residues
N288, L291A, S342A, and M425A involved in the phosphate
linkage and the G base recognition (Figure 2A) showed defects
when converting A2 to A1 (Figure 4A). Finally, we have established
in vitro deadenylation conditions wherein a cap-stimulatory
effect, to a level corresponding to native PARN, can be recovered
whenbacterially produced recombinant hPARN is used andhave
identified at least one hydrolytically active mutant polypeptide,
hPARN(W475A), that is deficient in both cap binding and the
cap-stimulatory effect. Taken together, these results suggest
that tryptophan residue 475 participates in both cap bindingrights reserved
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some extent, both structurally and functionally, with the active
site of PARN at the nuclease domain.
DISCUSSION
Crystal structures of eIF4E (Marcotrigiano et al., 1997), the
vaccinia virus protein Vp39 (Hodel et al., 1998), CBP20-CBP80
complex (Mazza et al., 2001), the scavenger mRNA decapping
enzyme (DcpS) (Chen et al., 2005; Gu et al., 2004), and the
nuclear import adaptor snurportin1 (Strasser et al., 2005) in
complex with cap analogs have been determined. A comparison
of these protein-cap complex structures has revealed a shared
mechanism for cap structure recognition (Figure 5). This
conserved mechanism is based on p-p or cation-p stacking
interaction between aromatic residues of the protein and the
methylated guanine moiety of the cap to discriminate a methyl-
ated guanine base from an unmethylated guanine (Hu et al.,
2003; Niedzwiecka et al., 2002). In eIF4E, CBP20, and VP39,
the 7-methyl guanosine moiety is sandwiched by two aromatic
residues from these proteins, whereas in DcpS, it is sandwiched
byW175 and L206 (Figure 5). Most recently, the crystal structure
of the central domain of influenza virus polymerase subunit PB2
in complex with m7GTP showed that the m7G base is sand-
wiched between F404 and H357 (Guilligay et al., 2008) (Figure 5).
In the snurportin1-m3
2,2,7GpppG complex, the cap analog is
self-stacked, providing the third stacking plane (Strasser et al.,
2005). Our structure showed that only one aromatic residue,
W468, stacks against the 7-methyl guanosine base (Figure 5).
To sum up, we have identified a novel mode of 7-methylgua-
nosine cap recognition by PARN. Although the stacking interac-
tion, salt bridges, direct and water-mediated hydrogen bonds,
and van der Waals contacts that contribute to the cap recogni-
tion by PARN are common among cap-binding proteins, PARN
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Figure 5. Comparisons of the m7G-Binding
Modes in eIF4E, VP39, CBP20, PB2, Dcps,
Snurportin1, and PARN
The guanosine bases are colored in green stick
models, and the residues involved in stacking
interactions with the guanosine base are colored
in yellow sticks and labeled.
is the only known example that exploits
one-sided stacking to stabilize the m7G
moiety and keeps an open space at the
other side of its aromatic ring. The less
efficient one-sided stacking in PARN is
supported by a large network of other
noncovalent contacts, especially those
stabilizing the phosphate linkage and
surrounding the first transcribed nucleo-
side. It was shown that PARN discrimi-
nated the 7-methylated 50 terminus
versus the nonmethylated one in the
enzymatic assays when we used PARN
purified from calf thymus (Martinez et al.,
2001; Martinez et al., 2000); hence, the
one-sided stacking provided by the platform made up by the in-
dol ring of W468 (W475 in human) seems to be the
minimal, necessary, andsufficient condition for specificity toward
the 7-methylguanosine cap structure.
The RNA recognition motif (RRM) is one of the most abundant
protein domains in eukaryotes and participates in many biolog-
ical processes, such as RNA editing, RNA splicing, RNA export,
translational regulation, and RNA degradation (Maris et al.,
2005). To date, there aremore than 30 structures of RRMs deter-
mined by NMR or X-ray crystallography. The RRMs share
a common ab fold structure with a babbab topology. The
b strands form an antiparallel b sheet and are packed against
by two a helices. Previous extensive biochemical studies on
the RRM of hPARN showed that this RRM binds both the cap
structure and poly(A) (Nilsson et al., 2007). In keeping with these
observations, our current structure indicates that PARN utilizes
the a1-b1 loop and b2 in the RRM domain to recognize the
m7G moiety and that the nuclease domain contacts the rest of
the cap molecule. The canonical RNA-binding site on the RRM
domain b face is still available for poly(A) binding.
To date, we have determined three structures of PARN—
hPARNn (residues 1–430) in native form, hPARNn (residues
1–430) in complex with poly(A), and the mPARNt-m7GpppG
complex—and have shown that PARN functions as a homo-
dimer. Given that we have not succeeded in observing all three
functional domains of PARN simultaneously in a single structure,
we reconstructed a homodimeric model of PARN by superim-
posing these three structures together given that the position
of the disordered R3H domain in the mPARNt-m7GpppG
complex is likely to be the same as in the apo-hPARNn (see
above) (Wu et al., 2005) (Figure 6). This model shows that the
RRM domain from one subunit, together with the R3H domain
from the other subunit, forms a circular structure that encloses
the active site. Consistent with this view, deletion mutationStructure 17, 276–286, February 13, 2009 ª2009 Elsevier Ltd All rights reserved 283
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cross-talked with the RRM domain to stabilize hPARN (Liu
et al., 2007). In this circular structure, the RRM domain may act
in conjunction with the R3H domain to increase the processivity
of PARN, although the underlying mechanism remains elusive.
We have characterized the cap-binding site of PARN through
a combined structural and functional analysis. Most importantly,
we show that the cap-binding and active sites of PARN partially
overlap both structurally and functionally within the nuclease
domain. This is a major surprise because earlier biochemical
studies clearly indicated that the two sites were structurally
and functionally separate from each other (Martinez et al.,
2001). This apparent discrepancy may be resolved by a putative
mechanism wherein the cap and poly(A) bind individually to two
subunits of PARN (Figure 6). The observations that the homodi-
meric PARN in the mPARNt-m7GpppG complex contains two
structurally distinct cap-binding sites are similar to those
observed in the Dcps structure (Gu et al., 2004). Although the
dramatically asymmetric cap-binding sites in Dcps suggested
an elegant autoregulatory mechanism to control scavenger
Figure 6. Model of Homodimeric PARN Containing All Three Func-
tional Domains
Color coding for the RRM and nuclease domains is as in Figure 1. The R3H
domain is colored in red. m7GpppG and poly(A) are shown in stick models
with carbon atoms colored in yellow and green, respectively.284 Structure 17, 276–286, February 13, 2009 ª2009 Elsevier Ltd AmRNA decapping, the functional implications of the distinct-
cap binding sites in PARNdo not seem very clear. The conforma-
tional changes that are induced upon cap binding might be
tightly coupled to the stimulatory effect of the 50 cap on the
poly(A) tail hydrolysis. However, the molecular basis of how the
cap binding is coordinated with the poly(A) binding to stimulate
hydrolysis remains to be elucidated.
In summary, the mPARNt-m7GpppG complex structure pre-
sented here reveals a novel cap-binding mode. Both the RRM
and the nuclease domains are involved in cap binding, with the
RRM recognizing the m7G base and the nuclease domain
providing additional binding affinity for the rest of the cap mole-
cule. Importantly, our structural and mutational data demon-
strated that the cap-binding site and the active site overlap
each other both structurally and functionally. Superposition of
all the PARN structures we have solved so far allows us to recon-
struct a homodimeric model of PARN. This model will be essen-
tial for further studies when elucidating molecular mechanisms
behind PARN action, including its catalytic activity, high speci-
ficity for poly(A), processivity, and the molecular details behind
the cap stimulatory effect on PARN.
EXPERIMENTAL PROCEDURES
Molecular Cloning
mPARNt was amplified from mouse full-length PARN cDNA (RZPD, Germany)
with a forward primer containing PreScission protease cutting site. The frag-
ment was cloned into a pET28a vector.
Site-Directed Mutagenesis
hPARN mutants were generated from pE33PARN (Ren et al., 2002) using
Quick-Change Site-Directed Mutagenesis kit (Stratagene) following the
protocol from the manufacturer. The mutations were introduced by using
primers named as the corresponding mutation and with sequences listed in
Table S2. All mutations were confirmed by DNA sequencing.
Protein Expression and Purification
mPARNt was expressed in Escherichia coli strain BL-21 STAR (Stratagene).
Cells were induced with 0.1 mM IPTG when OD600nm reached 0.6 and were
further incubated at 18C overnight. Selenomethione-substituted protein
was expressed by growing cells in a minimummedia containing 20 mg/L L-se-
leno-methione (Sigma). The cells were harvested and resuspended in a lysis
buffer (20 mM Tris [pH 8.0], 500 mM NaCl, and 2 mM benzamidine) containing
1mg/ml lysozyme. The cells were lysed using sonication and were centrifuged
at 18,000 g for 1 hr. The supernatant was loaded onto a Talon Metal Affinity
Resin (Clontech) column and was washed with at least 10 column volumes
of the lysis buffer containing 20mM imidazole. ThemPARNt protein was eluted
with the lysis buffer containing 200mM imidazole. The His tag was removed by
the PreScission protease (Amersham) at 4C overnight, and the target protein
was further purified using MonoQ and Superdex-200 columns (Amersham).
The protein was concentrated to about 10 mg/ml for crystallization.
Recombinant hPARN(D28A), hPARN(I34A), hPARN(N288A), hPARN
(L291A), hPARN(K326A), hPARN(N340A), hPARN(S342A), hPARN(M425A),
hPARN(R426A), and hPARN(W475A) were expressed from E. coli strain
BL21(DE3), as described elsewhere (Nilsson and Virtanen, 2006). Soluble re-
combinant polypeptides were purified using Talon Metal Affinity Resin (Clon-
tech). The amount of protein was measured using a BioRad protein assay
kit, and the purity was analyzed by gel electrophoresis (SDS-PAGE) followed
by silver or coomassie staining.
Preparation of RNA Substrates
A3 and A20 RNA substrates were purchased from Dharmacon Research.
Before usage, the substrates were deprotected according to the instructions
from the manufacturer. A3 or A20 (10 pmol) was 5
0-labeled with 20 pmolll rights reserved
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Crystal Structure of the PARN-Cap Complex[g-32P]-ATP (GE Healthcare, cat nr AA0068) using T4 polynucleotide kinase
(USB, cat nr 70031Z), and the reaction was incubated in 37C for 45 min.
The labeled nucleotides were resolved by 25% polyacrylamide gel, bands
cut out and eluted over night in water. The final concentrations of labeled oli-
go(A) were 2.5–25 nM. m7GpppG capped or noncapped L3(A30) was prepared
by in vitro transcription, as described elsewhere (Nilsson et al., 2007).
Crystallization, Data Collection, and Structure Determination
m7GpppG cap analog was added to the protein solution to a final concentra-
tion of 1 mM. The crystals of mPARNt with m7GpppG were grown in a buffer
containing 6–10% PEG6000, 100 mM MES [pH6.0], and 10 mM betaine by
use of the hanging-drop method. The crystals were cryo-protected in the
above crystallization condition with 35% Ethylene glycol and were frozen in
liquid nitrogen. A SeMet SAD data set was collected at ID14-4 in ESRF (Gre-
noble, France) and was processed with MOSFLM and CCP4 (CCP4, 1994).
The crystal belongs to space group P212121, with two molecules in the asym-
metric unit. The structure of mPARNt in complex m7GpppG was determined
with a combination of SeMet SAD and the molecular replacement method
using Phaser (McCoy et al., 2005). Our previous structure of the nuclease
domain of hPARNn (pdb code: 2A1R) and the NMR model of mouse RRM
(pdb code: 1WHV) were used as search models in the molecular replacement.
The phases generated by SeMet SAD phasing using SHARP (De la fortelle and
Bricogne, 1997) were combined with those from the model to calculate the
initial electron density map. Model rebuilding was carried out with Coot (Ems-
ley and Cowtan, 2004). The model was refined by CNS (Brunger et al., 1998)
and refmac5 (Murshudov et al., 1997). All data statistics are shown in Table 1.
Fluorescence Spectroscopy
Titrations were performed essentially as described elsewhere (Niedzwiecka
et al., 2007). The cap analogs were a kind gift of Edward Dar _zynkiewicz,
University of Warsaw. The protein samples were centrifuged for 10 min at
12,000 rpm at 4C. hPARN and mutants thereof were used at 0.06–0.5 mM
per monomer, in 20 mM HEPES-KOH (pH 7), 100 mM KCl, 1.5 mM MgCl2,
0.5 mM DTT, and 0.2 mM EDTA. Aliquots of 1 ml of increasing concentrations
(10 mM to 2 mM) of m7GTP or m7GpppG were injected manually to 1400 ml of
protein solution. Fluorescence measurements were run on Fluorolog-3 Spec-
trofluorometer (Horiba Jobin Yvon), at 20.0C in a thermostated quartz semi-
micro cuvette (Hellma), at an excitation and emission wavelengths of 280
and 320 nm (slit 1 and 10 nm), respectively. Fluorescence changes were moni-
tored continuously with the integration time of 30 s and the gap of 30 s for add-
ing the ligand, with slow magnetic stirring. During the gap, the excitation slit
was shut off to avoid photobleaching of the sample. The signal was normalized
by the reference photodiode current. Regressions were performed by means
of a nonlinear, least-squares method, using PRISM 3.02 (GraphPad Software,
USA). The final KD values were calculated as weighted averages from at least
three independent titration series.
PARN Deadenylation Assay
hPARN or hPARN mutant (50 nM) was incubated with 1 mM A3. Conditions for
the reaction were 25 mM HEPES (pH 7.0), 100 mM NaCl, 0.1 mg/ml BSA, and
2 mM MgCl2. The reactions (final volume, 10 ml) were incubated at 30
C for
10 min and were stopped by the addition of 2 ml of 0.5 M EDTA. Released
AMP products were separated from the reactions by one-dimensional TLC
by spotting 1 ml of the reaction on a polyethyleneimine cellulose F plate (Merck,
5579) and using 0.5 M LiCl as solvent. The plate was dried, exposed, and
scanned by a 400S PhosphorImager (Molecular Dynamics).
hPARN or hPARN mutant (10 nM) was incubated with 25 nM A20. Reaction
conditions were as described above. The reacted RNAwas separated by 25%
polyacrylamide (19:1 acrylamide:bis-acrylamide). The gel was exposed and
scanned by a 400S PhosphorImager (Molecular Dynamics).
hPARN or hPARN mutants (1–128 nM) were incubated with 10–50 nM
m7GpppG capped or noncapped L3(A30), as described above or when indi-
cated, in 50 mM KH2PO4/K2HPO4 (pH 7.0), 100 mM NaCl, 0.1 mg/ml BSA,
and 2 mMMgCl2. Released AMP products were separated from the reactions
by one-dimensional TLC by spotting 1 ml of the reaction on a polyethyleneimine
cellulose F plate (Merck, 5579) and using 0.4 M KH2PO4 (pH 3.5) (H3PO4) as
solvent. The plate was dried, exposed, and scanned with a 400S PhosphorIm-
ager (Molecular Dynamics).Structure 17, 276Isothermal Titration Calorimetry
The binding affinities of mPARNt to m7GpppG and 10-mer poly(A) (A10) were
determined using a VP-ITC microcalorimeter (Microcal, Inc). Twenty-nine
aliquots of 10 ml of 290 mMm7GpppG or 480 mMA10 in the syringe were titrated
against 15 mM mPARNt (concentration calculated per PARN monomer) in the
cell at 18C in the buffer containing 100mMKCl, 25 mM potassium phosphate
(pH 7.5), 1 mM DTT, and 5 mM EDTA. In the case of competition assay,
mPARNt was mixed with m7GpppG or A10 with molar ratio of 2.5:1 and was
titrated by A10 or m
7GpppG, respectively. The heat of dilution was measured
by additional injections of ligand after saturation. The titration curves were
analyzed usingMicroCal Origin software. The KD and KD
app values were calcu-
lated using the equation for the single-site model, where KD = 1/ Ka.
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